NLRP3 and experimental autoimmune encephalomyelitis: A potent and selective small-molecule inhibitor of NLRP3, MCC950, has been developed and shown to attenuate NLRP3-associated syndromes, including experimental autoimmune encephalomyelitis and cryopyrin-associated periodic syndrome, in mice7.